Lamotrigine and Stevens-Johnson Syndrome Prevention
Psychopharmacol Bull. 2021 Mar 16;51(2):96-114.ABSTRACTStevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related-common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in adverse reactions to specific drugs. HLAB*15:02 has been identified in the Chinese and others of Southeast Asian origin to increase susceptibility to lamotrigine and carbamazepine-induced SJS. Furthermore, patients of Japanese origin with HLAB*31:01 and Koreans with HLA-B*44:03 are also at increased risk of SJS after receiving the same two drugs. Of the antiepileptics, one most commonly associated with SJS is lamotrigine, a pre-synaptic voltage-gated sodium channel inhibitor. Lamotrigine is an antiepileptic drug of the phenyltriazine class that is indicated for the prevention of focal and generalized seizures in epileptic patients as well as monotherapy or adjunctive maintenance treatment for Bipolar disorder. The occurrence of SJS is not a rigid contraindication to lamotrigine reintroduction in the same patient. To facilitate this, manufacturers have developed a ...
Source: Psychopharmacology Bulletin - Category: Psychiatry & Psychology Authors: Amber N Edinoff Long H Nguyen Mary Jo Fitz-Gerald Erin Crane Kyle Lewis Samantha St Pierre Alan D Kaye Adam M Kaye Jessica S Kaye Rachel J Kaye Sonja A Gennuso Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research
More News: Allopurinol | Bipolar | Carbamazepine | China Health | Epilepsy | Food and Drug Administration (FDA) | Genetics | Japan Health | Lamictal | Mania | Psychology | Sodium